pre-ipo
Stage
About
Edesa Biotech is a clinical-stage biopharmaceutical company developing host-directed monoclonal antibody therapies to treat immune and inflammatory diseases such as acute respiratory distress syndrome (ARDS). Their drug candidates aim to modulate immune dysregulation across multiple diseases.
Explore Edesa Biotech's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.